Challenges of Indian Pharmaceutical Industries to Meet World Requirement during COVID-19 Pandemic
Keywords:India, Intellectual property, Health-care industry, Pharmaceutical sector, Contract Manufacturing Organizations, Production innovation, Active pharmaceutical ingredients
The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020, after the outbreak that was first reported in Wuhan, China in December 2019. The COVID-19 pandemic affected world economy including the pharmaceutical sector. The health crisis unleashed in the world because of this pandemic and the attempts of various countries and organizations in the world to contain it have also fuelled the greatest economic crisis in modern history. This study aims to access, analyze, and highlight opportunities and problems of the Indian pharmaceutical sector in the broader national health-care industry during the COVID-19 particularly for contract manufacturing The recent changes in the field, at the institutional and corporate levels, have placed India in the spotlight of the global pharmaceutical market, but several threats and weaknesses could limit this expansion. Descriptive and inferential analyses have been based on questionnaire, data extracted from authenticated data sources. Subsequently, a narrative strengths, weaknesses, opportunities, and threats analysis was performed based on the results of prior investigations and on qualitative data that were retrieved from a marketing intelligence examination to generate an overall scenario analysis. Indian pharmaceutical companies have faced several challenges on various fronts. In the home market, drug prices are controlled by the drug price control order; therefore, there is strong pressure on revenues and subsequently on costs. In the international market, threats derived from pharmaceutical multinational companies are emerging as tough obstacles to overcome. This study provides a global overview of the potential growth and development of the Indian pharmaceutical sector, comparing it with internal trends and external competition. The most relevant contribution of the research relies on the shift to innovative production that Indian companies must adopt (after years of focusing only on generic drugs), and in this vein, appropriate industrial marketing solutions are indispensable.
How to Cite
Copyright (c) 2022 Amit Chandna, Sourabh Jain, Samriti Vohra
This work is licensed under a Creative Commons Attribution 4.0 International License.
Asian Pacific Journal of Health Sciences applies the Creative Commons Attribution (CC-BY) license to published articles. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. Appropriate attribution can be provided by simply citing the original article.